Laidlaw initiated coverage of central nervous system drug developer Silo Pharma (NASDAQ:SILO) with a buy rating, citing valuation and the prospects for two of its drug candidates, SPC-15 and SP-26.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results